Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019
February 14, 2020 at 11:03 pm
Share
Rasna Therapeutics, Inc. announced earnings results for the first quarter ended December 31, 2019. For the first quarter, the company announced operating loss was USD 149,281 compared to USD 399,328 a year ago. Net loss was USD 158,042 compared to USD 401,303 a year ago. Basic eps - continuing operations was USD 0 compared to basic loss per share from continuing operations of USD 0.01 a year ago.
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
ACTAVIA LIFE SCIENCES, INC. 
